Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. Summary
    AVRO   US05455M1009

AVROBIO, INC.

(AVRO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
5.57(c) 5.67(c) 5.58(c) 5.54(c) 5.52(c) Last
198 241 150 669 202 307 133 581 169 695 Volume
-3.97% +1.80% -1.59% -0.72% -0.36% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -125 M - -
Net cash position 2021 156 M - -
P/E ratio 2021 -1,91x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -148 M - -
Net cash position 2022 126 M - -
P/E ratio 2022 -1,72x
Yield 2022 -
Capitalization 241 M 241 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 121
Free-Float 97,1%
More Financials
Company
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with a lentiviral vector to insert a functional copy of the gene that is defective in the... 
Sector
Biotechnology & Medical Research
Calendar
10/28 | 10:30amPresentation
More about the company
Ratings of AVROBIO, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about AVROBIO, INC.
10/20AVROBIO : to Present at the Jefferies Virtual Gene Therapy/Editing Summit
BU
10/19AVROBIO : Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry ..
PU
10/19AVROBIO, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
10/19AVROBIO : Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry ..
BU
10/19AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry..
CI
10/12AVROBIO : Morgan Stanley Adjusts AVROBIO's Price Target to $25 from $27, Keeps Overweight ..
MT
10/07PRESS RELEASE : Heidelberg Pharma AG: Interim Management Statement on the First Nine Month..
DJ
10/06AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
10/06AVROBIO : to Present New Clinical and Preclinical Data Across Multiple Programs at the ESG..
BU
10/06AVROBIO, Inc. to Present New Clinical and Preclinical Data Across Multiple Programs at ..
CI
10/05AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/20AVROBIO, INC.(NASDAQGS : AVRO) dropped from S&P Biotechnology Select Industry Index
CI
09/15MAGENTA THERAPEUTICS : Gets FDA Clearance for Leukemia Drug Trial, Plans Phase 1/2 Study i..
MT
09/15Magenta Therapeutics Gets IND Clearance for MGTA-117
DJ
09/06AVROBIO : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
More news
News in other languages on AVROBIO, INC.
10/07HEIDELBERG PHARMA AG : Zwischenmitteilung für die ersten neun Monate 2021
More news
Analyst Recommendations on AVROBIO, INC.
More recommendations
Chart AVROBIO, INC.
Duration : Period :
AVROBIO, Inc. Technical Analysis Chart | AVRO | US05455M1009 | MarketScreener
Technical analysis trends AVROBIO, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 5,52 $
Average target price 23,44 $
Spread / Average Target 325%
EPS Revisions
Managers and Directors
Geoff MacKay President, Chief Executive Officer & Director
Erik Ostrowski Chief Financial Officer & Treasurer
Bruce Lee Booth Chairman
Christopher Mason Chief Scientific Officer
Kim Raineri Chief Manufacturing & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
AVROBIO, INC.-60.40%241
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610